Inaqovi

Decitabine, the active ingredient in Inaqovi, together with cedazuridine, is a DNA methyltransferase inhibitor presented as a 35 mg decitabine / 100 mg cedazuridine oral tablet for oral use. It treats myelodysplastic syndromes and acute myeloid leukemia in adult patients.

GNH USA supplies Inaqovi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Inaqovi is used in the treatment of hematologic malignancies that involve abnormal DNA methylation.

Myelodysplastic syndromes (MDS): improves blood counts and reduces risk of progression to acute leukemia. Acute myeloid leukemia (AML): induces remission and prolongs survival in eligible patients. Older adults with AML who are not candidates for intensive chemotherapy: provides a less intensive oral therapeutic option.

Common Side Effects: - Nausea - Fatigue - Diarrhoea or constipation - Fever - Decreased blood counts (neutropenia, thrombocytopenia)

Serious or Rare Side Effects: - Severe infections - Liver toxicity (elevated transaminases) - Pulmonary infiltrates or interstitial lung disease - Tumour lysis syndrome - Significant bleeding events - Cardiac arrhythmias

Before initiating therapy, clinicians should assess baseline organ function and monitor patients closely. - Monitor blood counts: perform regular complete blood count assessments. - Assess liver function: check hepatic enzymes periodically. - Evaluate renal function: adjust care for impaired clearance. - Avoid in patients with active uncontrolled infection. - Use effective contraception: both male and female patients of reproductive potential should employ reliable birth control. - Store at ambient temperature: keep in the original pack, protect from moisture.

Inaqovi may interact with several concomitant medications.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce drug exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - NSAIDs: may exacerbate gastrointestinal toxicity. - Antifungal agents (e.g., fluconazole): can increase plasma levels of decitabine. - Allopurinol: potential for hypersensitivity reactions.